ASCO 2013 Report – Lambrolizumab immunotherapy shows efficacy in advanced melanoma
Researchers report that investigative lambrolizumab has shown promising results, in advanced melanoma, with manageable side effects.
Researchers report that investigative lambrolizumab has shown promising results, in advanced melanoma, with manageable side effects.
by Bruce Sylvester – over 30,000 clinicians and researchers attended the American Society of Clinical Oncology 2013 annual meeting in Chicago on May 31-June 4. Among the most… read more.
by Peter Mas Mollinedo – Investigators report that the link between asthma and early childhood use of acetaminophen or ibuprofen could be the result of underlying respiratory infections,… read more.
by Peter Mas Mollinedo – Vegetarians have a 32% lower risk of hospitalization or death from heart disease than persons who eat meat and fish, researchers from the… read more.
Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study.
by Peter Mas Mollinedo – Investigators report that current marijuana users have achieved significantly lower fasting insulin, and are less likely than non-users to be insulin resistant, even… read more.
by Bruce Sylvester – Nine thousand clinicians gathered at the 2013 annual meeting of the European Association for the Study of the Liver/International Liver Congress in Amsterdam on… read more.
The drug erythropoietin, often called EPO, is banned from sports because it is believed to enhance an athlete’s performance and give people who use it an unfair advantage… read more.
Mind-body intervention can help to regulate stress hormone levels. Practicing a form of meditation and stretching can help relieve symptoms of post-traumatic stress disorder and normalize stress hormone… read more.
Gestation diabetes risk can be identified through biomarker levels during first trimester. Levels of a biomarker in a pregnant woman’s blood can help physicians gauge her risk of… read more.
Probiotics have significantly reduced development of hepatic encephalopathy researchers announced at EASL/International Liver Congress.
Hepatitis C patients treated with Merck’s investigative MK-5172, an oral NS3/4A protease inhibitor, combined with 24 or 48 weeks of peginterferon alfa 2b (Pegasys/ Roche) and ribavirin (Ribasphere/… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.